D.A. Davidson & Co’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.81M Buy
30,619
+8,198
+37% +$1.54M 0.03% 387
2026
Q1
$4.42M Buy
22,421
+10,262
+84% +$1.98M 0.03% 435
2025
Q4
$2.24M Sell
12,159
-3,078
-20% -$540K 0.01% 633
2025
Q3
$2.34M Sell
15,237
-3,345
-18% -$506K 0.02% 598
2025
Q2
$2.6M Buy
18,582
+555
+3% +$77.8K 0.02% 532
2025
Q1
$2.65M Sell
18,027
-31
-0.2% -$4.49K 0.02% 493
2024
Q4
$2.37M Buy
18,058
+5,128
+40% +$718K 0.02% 506
2024
Q3
$2.01M Sell
12,930
-3,917
-23% -$632K 0.02% 547
2024
Q2
$2.63M Buy
16,847
+1,467
+10% +$221K 0.02% 460
2024
Q1
$2.08M Sell
15,380
-376
-2% -$49.8K 0.02% 520
2023
Q4
$2.12M Buy
15,756
+3,139
+25% +$408K 0.02% 487
2023
Q3
$1.71M Buy
12,617
+907
+8% +$124K 0.02% 515
2023
Q2
$1.68M Sell
11,710
-28
-0.2% -$4.12K 0.02% 529
2023
Q1
$1.63M Sell
11,738
-823
-7% -$111K 0.02% 516
2022
Q4
$1.71M Buy
12,561
+193
+2% +$24.2K 0.02% 485
2022
Q3
$1.36M Buy
12,368
+1,627
+15% +$206K 0.02% 501
2022
Q2
$1.42M Buy
10,741
+876
+9% +$115K 0.02% 508
2022
Q1
$1.31M Buy
9,865
+379
+4% +$45.5K 0.01% 565
2021
Q4
$1.11M Sell
9,486
-306
-3% -$36K 0.01% 626
2021
Q3
$1.18M Buy
9,792
+932
+11% +$108K 0.01% 583
2021
Q2
$1.06M Buy
8,860
+548
+7% +$60.1K 0.01% 613
2021
Q1
$827K Sell
8,312
-315
-4% -$31.7K 0.01% 644
2020
Q4
$865K Sell
8,627
-3
-0% -$318 0.01% 542
2020
Q3
$946K Buy
8,630
+536
+7% +$59.6K 0.02% 460
2020
Q2
$856K Sell
8,094
-73
-0.9% -$7.54K 0.02% 477
2020
Q1
$728K Sell
8,167
-615
-7% -$57.9K 0.01% 513
2019
Q4
$877K Sell
8,782
-205
-2% -$19.3K 0.01% 536
2019
Q3
$801K Buy
8,987
+92
+1% +$7.98K 0.01% 533
2019
Q2
$734K Sell
8,895
-1,347
-13% -$106K 0.01% 540
2019
Q1
$821K Sell
10,242
-5,276
-34% -$416K 0.01% 555
2018
Q4
$1.18M Sell
15,518
-803
-5% -$62.7K 0.02% 443
2018
Q3
$1.29M Buy
16,321
+613
+4% +$46.4K 0.02% 452
2018
Q2
$1.1M Buy
15,708
+5,877
+60% +$423K 0.02% 467
2018
Q1
$688K Buy
9,831
+576
+6% +$39.9K 0.01% 586
2017
Q4
$642K Buy
9,255
+966
+12% +$65.1K 0.01% 584
2017
Q3
$561K Buy
8,289
+545
+7% +$34.4K 0.01% 642
2017
Q2
$527K Buy
7,744
+4,518
+140% +$295K 0.01% 610
2017
Q1
$200K Sell
3,226
-834
-21% -$48.5K ﹤0.01% 937
2016
Q4
$220K Sell
4,060
-7,490
-65% -$425K 0.01% 961
2016
Q3
$757K Buy
11,550
+9,397
+436% +$614K 0.02% 528
2016
Q2
$127K Buy
2,153
+50
+2% +$2.9K ﹤0.01% 1034
2016
Q1
$116K Sell
2,103
-97
-4% -$5.83K ﹤0.01% 1060
2015
Q4
$147K Buy
2,200
+6
+0.3% +$393 ﹤0.01% 956
2015
Q3
$138K Sell
2,194
-238
-10% -$15.7K ﹤0.01% 965
2015
Q2
$152K Buy
2,432
+85
+4% +$5.82K 0.01% 968
2015
Q1
$159K Buy
2,347
+272
+13% +$18.9K 0.01% 953
2014
Q4
$144K Sell
2,075
-98
-5% -$7.02K ﹤0.01% 984
2014
Q3
$154K Sell
2,173
-327
-13% -$23.9K 0.01% 962
2014
Q2
$184K Sell
2,500
-4,762
-66% -$344K 0.01% 927
2014
Q1
$470K Sell
7,262
-952
-12% -$61.5K 0.02% 626
2013
Q4
$485K Buy
8,214
+1,359
+20% +$73.8K 0.02% 588
2013
Q3
$354K Sell
6,855
-530
-7% -$26.6K 0.02% 563
2013
Q2
$348K Buy
+7,385
New +$376K 0.02% 547

Other funds holding AZN

D.A. Davidson & Co's AZN Position: Q2 2026 in Review

D.A. Davidson & Co increased its AstraZeneca (AZN) stake by 37% in Q2 2026, buying an estimated $1.54M and bringing the position to 30,619 shares worth $5.81M. The position accounts for 0.03% of the portfolio, ranked #387.

D.A. Davidson & Co first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • D.A. Davidson & Co held 30,619 shares of AstraZeneca worth $5.81M as of Q2 2026.
  • D.A. Davidson & Co bought 8,198 AstraZeneca shares in Q2 2026, an estimated $1.54M.
  • AstraZeneca made up 0.03% of D.A. Davidson & Co's portfolio in Q2 2026, its #387 holding.
  • D.A. Davidson & Co first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.